07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Pevion Biotech, NovaDigm, Italian National Health Institute deal

NovaDigm received exclusive, worldwide rights to Candida albicans secretory aspartyl proteinase 2 ( Sap2 ), a Candida vaccine antigen, from Pevion and Italian National Health Institute. NovaDigm plans to develop a multi-antigen Candida vaccine, but...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Clinical News

Candida vaccine: Additional Phase I data

Data from 6 healthy volunteers in the low-dose cohort of a Swiss Phase I trial showed that a booster vaccination with PEV7 given 14 months after the last of 3 primary immunizations produced detectable anti-SAP2...